FIBER-ON-TABLET 500 MG — DIN 02245870
POLYCARBOPHIL (CALCIUM POLYCARBOPHIL) : 500 MG · JAMP PHARMA CORPORATION · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is FIBER-ON-TABLET?
FIBER-ON-TABLET 500 MG contains POLYCARBOPHIL (CALCIUM POLYCARBOPHIL) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02245870, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 07-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
Is there a generic Polycarbophil Calcium in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Polycarbophil Calcium, across 5 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAYER INC | 1 | 0 | PHILLIP'S FIBRECAPS | No marketed DIN |
| GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC | 1 | 0 | PRODIEM BULK FIBRE THERAPY | No marketed DIN |
| JAMP PHARMA CORPORATION | 1 | 0 | FIBER-ON-TABLET | No marketed DIN |
| NUMARK LABORATORIES, INC. | 1 | 0 | EQUALACTIN - TAB 625MG | No marketed DIN |
| PERRIGO INTERNATIONAL | 1 | 0 | FIBRE LAXATIVE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Polycarbophil Calcium |
|---|---|
| ATC code | A06AC08 |
| AHFS class | 56:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02245870 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2245870 |
| Brand name | FIBER-ON-TABLET |
| Generic / active ingredient | POLYCARBOPHIL (CALCIUM POLYCARBOPHIL) : 500 MG |
| Market authorization holder | JAMP PHARMA CORPORATION |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A06AC08 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A06AC |
| Current status | DORMANT |
| Status date | 07-Aug-2017 |
| Original market date | 2002-05-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| EQUALACTIN - TAB 625MG | 625 MG | TABLET | NUMARK LABORATORIES, INC. | CANCELLED POST MARKET | 02129450 |
| FIBRE LAXATIVE | 500 MG | TABLET | PERRIGO INTERNATIONAL | CANCELLED POST MARKET | 02247187 |
| PHILLIP'S FIBRECAPS | 500 MG | TABLET | BAYER INC | APPROVED | 02244117 |
| PRODIEM BULK FIBRE THERAPY | 625 MG | TABLET | GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC | CANCELLED POST MARKET | 02246645 |
2 · Same class — other molecules in ATC A06AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ispaghula (Psylla Seeds) | COLON PURE · EASY LAX PWR 480MG · EASY LAX SUGER FREE 100% · FIBERMAX PWR 7GM/TBS · +46 more | 52 | 0 | Not in Canada |
| Ispaghula, Combinations | ARNOLD EHRET HERBAL LAXATIVE · ARNOLD EHRET INNERTABS · FLORALAX · HERBAL FIBRE 650 - CAP · +4 more | 8 | 0 | Not in Canada |
| Methylcellulose | ENTROCEL SOLUTION 1.8% · METHYLAX · PRODIEM BULK FIBRE THERAPY POWDER · PRODIEM BULK FIBRE THERAPY POWDER SUGAR FREE · +2 more | 6 | 0 | Not in Canada |
| Polycarbophil Calcium | EQUALACTIN - TAB 625MG · FIBER-ON-TABLET · FIBRE LAXATIVE · PHILLIP'S FIBRECAPS · +1 more | 5 | 0 | Not in Canada |
| Triticum (Wheat Fibre) | FIBRE TABS 500MG · FIBYRAX - TABLET · FIBYRAX TAB 469MG · HERB-FIBE CHEWABLE WAFERS | 4 | 0 | Not in Canada |
| Linseed | FLAX SEED PWS 1000MG/GM · GRAINE DE LIN | 3 | 0 | Not in Canada |
| Sterculia | NORMACOL PWR 62% | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A06AB | Bisacodyl · Bisacodyl, Combinations · Cascara · Cascara, Combinations · Castor Oil · +9 more | 239 | 25 |
| A06AA | Docusate Sodium · Docusate Sodium, Combinations · Liquid Paraffin · Liquid Paraffin, Combinations | 144 | 22 |
| A06AD | Lactulose · Macrogol · Macrogol, Combinations · Magnesium Oxide · Magnesium Sulphate · +5 more | 86 | 21 |
| A06AX | Glycerol · Linaclotide · Lubiprostone · Other Laxatives · Plecanatide · +2 more | 30 | 14 |
| A06AH | Methylnaltrexone Bromide · Naloxegol | 5 | 3 |
| A06AG | Bisacodyl · Combinations · Docusate Sodium, Incl Combinations · Sodium Phosphate | 7 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.